Markota, Matej
Coombes, Brandon J.
Larrabee, Beth R.
McElroy, Susan L.
Bond, David J.
Veldic, Marin
Colby, Colin L.
Chauhan, Mohit
Cuellar-Barboza, Alfredo B.
Fuentes, Manuel
Kung, Simon
Prieto, Miguel L.
Rummans, Teresa A.
Bobo, William V.
Frye, Mark A.
Biernacka, Joanna M. http://orcid.org/0000-0001-9350-4440
Funding for this research was provided by:
Marriott Foundation
Article History
Received: 26 April 2018
Revised: 13 July 2018
Accepted: 5 August 2018
First Online: 10 September 2018
Conflict of interest
: Dr. McElroy is a consultant to or member of the scientific advisory boards of Bracket, F. Hoffmann-La Roche Ltd., MedAvante, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Shire, and Sunovion. She is a principal or co-investigator on studies sponsored by the Allergan, Brainsway, Marriott Foundation, Myriad, National Institute of Mental Health, Novo Nordisk, Shire, and Sunovion. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. The other authors declare that they have no conflict of interest.